Diagnostics, Genetics, Imaging

Qiagen to Market AR-V7 Genetic Test That Shows If Prostate Cancer Responds to Enzalutamide (Xtandi) or Abiraterone (Zytiga).

Enzalutamide (Xtandi®) and abiraterone acetate (Zytiga®) are two approved hormone therapies commonly prescribed for men with hormone-resistant advanced prostate cancer. They block the androgen receptor signaling that is essential to the cancer’s growth. Although they represent breakthroughs in metastatic treatment, 20 to 40 percent of patients fail to respond to them.  These men with advanced more »

Updated PSA Screening Guidelines Now Stress Patient Choice

When three different prostate cancer websites post the same subject article, it is significant. According to the April 11th MedLinePlus from the U.S. National Library of Medicine, in a significant shift, a key health advisory panel plans to soften its recommendation against prostate-specific antigen (PSA) screening for detecting prostate cancer. In 2012, the U.S. Preventive Services more »

Men in Their 20’s and 30’s With a Specific Early Balding Pattern May Be at Higher Risk of Aggressive Prostate Cancer

When I come across a newsworthy article of interest, I usually summarize it on this post and link the reader to the entire article for more information. This is an exception as the original article from the Prostate Cancer Foundation (March 30th, 2017) contains specific visual and verbal information; hence I refer you to the more »

Predicting Prostate Cancer Metastasis and Mortality Using Decipher Genomic Score

The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality (PCSM) using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen (hormonal) deprivation, according to a mixed-cohort study presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida. Decipher more »

Identifying Suitable Candidates for Active Surveillance in Prostate Cancer

This review is designed for physicians and patients who have access to multiparametric MRI technology available in several major health research institutions. A recent article by Drs. Peter Choyke and Stacy Loeb  (from the National Cancer Institute, NIH) in the journal Oncology and e mailed through the CancerNetwork provided a important summary of active surveillance, more »

An Excellent Review of Current Imaging and Positron Emission Tomography (PET) Scanning and Their Use in Managing Recurrent and Advanced Disease

This website initially posted a review of positron emission tomography (PET) scanning on March 9th, 2015. More recently, the Prostate Cancer Research Institute (PCRI) November Insights contained an updated and very informative review of the latest PET imaging techniques for managing recurrent and advanced prostate cancer. Their major utilities, advantages and their limitations are discussed more »

Men with Advanced Prostate Cancer Should Consider Genetic Testing

In the light of recent discoveries (recently posted on this website) that some advanced prostate cancer patients harbor specific genetic mutations, a recent study summarized in the July 7th National Library of Medicine MedLine Plus suggested that testing for inherited abnormalities in DNA repair genes could provide patients and family members important information about their more »

High Prostate Cancer Risk Linked to Inherited Mutations in DNA-Repair Genes.

Mutations in DNA-repair genes, including the breast cancer genes BRCA1 and BRCA2, are involved in an inherited high risk of prostate cancer and, potentially, the risk of an aggressive cancer, according to researchers at Fred Hutchinson Cancer Research Center and the University of Washington. The study entitled, “Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer”,  published in The more »

Potential Diagnosis of Prostate Cancer Using Urine Biomarker Protein Signatures.

A recent study revealed protein biomarker combinations in urine that are unique to prostate cancer and 2 of its stages.  A team from the University Health Network in Toronto Canada analyzed urine samples from 50 patients with prostate cancer — 37 with prostate-confined tumors and 13 with tumors that spread — and 24 healthy controls. A targeted protein screen more »

High Prostate Cancer Risk Linked to Inherited Mutations in DNA-repair Genes.

Mutations in DNA-repair genes, including the breast cancer genes BRCA1 and BRCA2, are involved in an inherited high risk of prostate cancer and, potentially, the risk of an aggressive cancer, according to researchers at Fred Hutchinson Cancer Research Center and the University of Washington. The study, “Inherited DNA -Repair Gene Mutations in Men with Metastatic Prostate Cancer” published in The more »

The FDA Approves a New Diagnostic Imaging Agent (Axumin) to Detect Recurrent Prostate Cancer.

Several positron emission tomography (PET) scans (including C-11 choline and acetate PET scans) exist whose purpose is to detect the location of recurrent prostate cancer when the PSA is at low levels. Within the last few days, the U.S. Food and Drug Administration approved another scan using an injected radioactive agent called Axumin. The following more »

Low Vitamin D Levels May Signal More Aggressive Prostate Cancer But Don’t Expect Supplements to Ward Off Fast-Growing Tumors.

A Northwestern University study of 190 men of median age 64 having their prostate removed found those with low vitamin D levels were more likely to have rapidly growing tumors than those with normal levels of the “sunshine” vitamin.  The study was published on-line in the Journal of Clinical Oncology. The researchers found that nearly more »

Prostate Cancer Lesions Accurately Detected by New Imaging Agent

Current tests to initially detect prostate cancer rely on biopsies.  Scans such as bone and CT scans, and choline-11 and acetate-11 PET scans are used to identify sites of cancer metastases.  Researchers at Thomas Jefferson University have now developed a new imaging technique to detect prostate cancer cells and malignant lesions.  Their technique is both more »

Predicting Prostate Cancer’s Future Behavior

Developing an accurate prognosis, i.e., predicting how a man’s cancer is likely to behave in the future, is the first and most important step toward optimal care. Future predictions are often looked at with some suspicion. With prostate cancer, however, our power to anticipate future cancer behavior is quite accurate unless there is a lack more »